Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Michelle Melisko (ucsf)
Headshot of Michelle Melisko
Michelle Melisko

Description

Summary

Official Title

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

Details

Keywords

Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation, Breast Neoplasms, Olaparib, OLAPARIB QD GERMLINE MUTATION, OLAPARIB QD GERMLINE MUTATION - EXPANSION, OLAPARIB QD SOMATIC MUTATION, OLAPARIB QD SOMATIC MUTATION - EXPANSION

Eligibility

Locations

  • University of California, San Francisco
    San Francisco California 94143 United States
  • University of Washington Fred Hutchinson Cancer Care
    Seattle Washington 98109 United States

Lead Scientist at University of California Health

  • Michelle Melisko (ucsf)
    Dr. Michelle E. Melisko is a cancer specialist with expertise in breast cancer treatment and research. She is interested in testing new chemotherapy combinations, biological therapies and immunotherapies for breast cancer, with a particular focus on treatment of cancer that has spread to the brain.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Beth Israel Deaconess Medical Center
ID
NCT03344965
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 114 study participants
Last Updated